the fact that the more exciting aspects of the Brilacidin franchise are attracting all of the attention is wonderful: the anti inflammatory stuff is so new and different in medicine, and there are so many potential indications for use
Acne? conjunctivitis? blepharitis? maybe crohn's?
shareholders have to feel warm and fuzzy over initial B-OM and now new B-UP results, and I have a lot of faith in Brilacidin's protean uses
yes, I am of little faith in P Glad to be dissuaded by stellar data
by the way- the company does not know how the drug works.....recall Bertolino saying that it is not due to abacavir.
Market Data 
Markets 
AI
